Belrestotug is under clinical development by ITeos Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Belrestotug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Belrestotug overview
EOS-448 is under development for the treatment of solid tumors, non-small cell lung cancer, squamous non-small cell lung cancer, PD-1 resistant melanoma and head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a checkpoint blocking antibody acts by targeting TIGIT.
It was also under development for the treatment of relapsed or refractory multiple myeloma.
ITeos Therapeutics overview
iTeos Therapeutics is a clinical-stage biopharmaceutical company that primarily focuses on the discovery and development of immuno-oncology therapeutics. The company’s pipeline products include Belrestotug (EOS-448), Inupadenant, and EOS-984. iTeos Therapeutics’ products are primarily used in the healthcare industry, specifically in the treatment of patients with advanced solid tumors. Its service includes to carries out clinical trials for inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy. The company operates in Belgium and the US. iTeos Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Belrestotug’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
